
In a phase 2 trial of sovleplenib for warm autoimmune haemolytic anaemia, 67% of patients achieved a haemoglobin response by week 24, with a durable response in 48%. Adverse events were common but manageable, with no grade 4 or 5 events. Phase 3 is ongoing.
Like
Save
Share